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Background: The goal of this study was to determine a predominant cell type expressing fractalkine receptor
(CX3CR1) in mature ovarian teratomas and to establish functional significance of its expression in cell differentiation.
Methods: Specimens of ovarian teratoma and human fetal tissues were analyzed by immunohistochemistry for
CX3CR1expression. Ovarian teratocarcinoma cell line PA-1 was used as a model for cell differentiation.
Results: We found that the majority of the specimens contained CX3CR1-positive cells of epidermal lineage. Skin
keratinocytes in fetal tissues were also CX3CR1- positive. PA-1 cells with downregulated CX3CR1 failed to express a
skin keratinocyte marker cytokeratin 14 when cultured on Matrigel in the presence of a morphogen, bone
morphogenic protein 4 (BMP-4), as compared to those expressing scrambled shRNA.
Conclusions: Here we demonstrate that CX3CR1 is expressed in both normally (fetal skin) and abnormally (ovarian
teratoma) differentiated keratinocytes and is required for cell differentiation into epidermal lineage.
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Ovarian teratoma (dermoid cyst) is a benign tumor
originating in germ cells. This tumor is one of the most
common germ cell tumors and accounts for up to 20%
of all ovarian cysts [1]. Ovarian teratoma is the most
common tumor associated with pregnancy [2]. Gener-
ally, ovarian teratomas are cured by a complete surgical
resection; however, some cases could give rise to a ma-
lignant disease [3,4]. Ovarian teratomas could be of both
homozygous and heterozygous origin, as well as the
mixture of the two, and it has been previously suggested
that several mechanisms could lead to their develop-
ment, including failure of meiosis I, failure of meiosis II,
or duplication of a mature ovum [5]. Mature ovarian
teratomas often contain a mixture of fully differentiated
tissues from all three cell layers, ectodermal, endoder-
mal, and mesodermal, resulting in formation of skin,* Correspondence: mvb@uic.edu
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reproduction in any medium, provided the orhair follicle, sebaceous gland, bone, teeth, thyroid, and
other cell types [6,7].
Our previous data obtained using a limited number of
subjects suggested that a chemokine receptor fractalkine
(CX3CR1) is expressed in ovarian teratomas [8]. CX3CR1
is a G protein-coupled receptor with multiple functions
in both the normal state and disease [9,10]. CX3CR1 is ac-
tivated by its highly specific ligand fractalkine (CX3CL1)
[11]. It has been shown that CX3CL1/CX3CR1 axis plays a
role in differentiation of osteoclasts [12] and development
of dendritic cells [13], but its role in skin differentiation
has not been described.
The goal of this study was to determine the predomin-
ant type of CX3CR1-positive cells in ovarian teratomas.
We also aimed to determine whether the same cell type
(s) are CX3CR1-positive during the normal develop-
ment. Lastly, using a cell culture model, we intended to
establish whether CX3CR1 expression is required for
cell differentiation.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Expression of CX3CR1 in human specimens of ovarian teratoma
Position Number Sex Age Organ Pathology Grade Type Tissue type Intensity* Location** Percentage***
A1 1 F 28 Ovary Mature teratoma - Benign Sebaceous 2.5 C 100
A1 1 F 28 Ovary Mature teratoma - Benign Apocrine 1 C 10
A2 2 F 24 Ovary Mature teratoma - Benign Skin 2 C 20
A2 2 F 24 Ovary Mature teratoma - Benign Lymphocytes 3 N 90
A3 3 F 26 Ovary Mature teratoma - Benign NR
A4 4 F 33 Ovary Mature teratoma - Benign Skin 3 C 100
A4 4 F 33 Ovary Mature teratoma - Benign Sebaceous 3 C 100
A5 5 F 48 Ovary Mature teratoma - Benign Follicle 3 C 100
A6 6 F 19 Ovary Mature teratoma - Benign Skin 3 C 100
A6 6 F 19 Ovary Mature teratoma - Benign Endothelium 1.5 C 90
A7 7 F 52 Ovary Mature teratoma - Benign Skin 2.5 C 100
A7 7 F 52 Ovary Mature teratoma - Benign Sebaceous 2.5 C 100
A8 8 F 27 Ovary Mature teratoma - Benign Skin 2 C 100
A8 8 F 27 Ovary Mature teratoma - Benign Apocrine 3 C 100
A8 8 F 27 Ovary Mature teratoma - Benign Lymph 3 NM 50
A9 9 F 22 Ovary Mature teratoma - Benign Sebaceous 3 C 100
A10 10 F 54 Ovary Mature teratoma - Benign Skin 2 C 100
A10 10 F 54 Ovary Mature teratoma - Benign Sebaceous 2.5 C 100
B1 11 F 58 Ovary Mature teratoma - Benign Adipose 1 C 80
B1 11 F 58 Ovary Mature teratoma - Benign Adipose 3 M 40
B2 12 F 32 Ovary Mature teratoma - Benign Skin 2 C 100
B2 12 F 32 Ovary Mature teratoma - Benign Follicle 2.5 C 100
B2 12 F 32 Ovary Mature teratoma - Benign Sebaceous 3 C 100
B3 13 F 28 Ovary Mature teratoma - Benign NR
B4 14 F 40 Ovary Mature teratoma - Benign Adipose 1 C 60
B4 14 F 40 Ovary Mature teratoma - Benign Adipose 3 M 40
B5 15 F 26 Ovary Mature teratoma - Benign Sebaceous 3 C 70
B5 15 F 26 Ovary Mature teratoma - Benign Apocrine 3 C 100
B6 16 F 39 Ovary Mature teratoma - Benign Endothelium 3 C 100
B6 16 F 39 Ovary Mature teratoma - Benign Lymphocytes 3 N 70
B7 17 F 23 Ovary Mature teratoma - Benign Lymphocytes 3 N 40
B7 17 F 23 Ovary Mature teratoma - Benign Apocrine 2.5 C 30
B8 18 F 32 Ovary Mature teratoma - Benign Sebaceous 3 C 100
B8 18 F 32 Ovary Mature teratoma - Benign Skin 3 C 100
B8 18 F 32 Ovary Mature teratoma - Benign Thyroid 3 C 80
B9 19 F 29 Ovary Mature teratoma - Benign Thyroid 3 C 80
B10 20 F 30 Ovary Mature teratoma - Benign Follicle 2 C 100
C1 21 F 40 Ovary Mature teratoma - Benign Sebaceous 3 C 100
C1 21 F 40 Ovary Mature teratoma - Benign Skin 1.5 C 100
C2 22 F 35 Ovary Mature teratoma - Benign Sebaceous 3 C 100
C2 22 F 35 Ovary Mature teratoma - Benign Skin 3 C 100
C3 23 F 49 Ovary Mature teratoma - Benign Lymphocytes 3 N 10
C4 24 F 51 Ovary Mature teratoma - Benign Skin 3 C 100
C5 25 F 22 Ovary Mature teratoma - Benign Skin 2 C 100
Rooper et al. Journal of Ovarian Research 2013, 6:57 Page 2 of 12
http://www.ovarianresearch.com/content/6/1/57
Table 1 Expression of CX3CR1 in human specimens of ovarian teratoma (Continued)
C5 25 F 22 Ovary Mature teratoma - Benign Lymphocytes 2 N 10
C6 26 F 69 Ovary Mature teratoma - Benign NR
C7 27 F 35 Ovary Mature teratoma - Benign Sebaceous 3 C 100
C7 27 F 35 Ovary Mature teratoma - Benign Follicle 2 C 100
C7 27 F 35 Ovary Mature teratoma - Benign Apocrine 2.5 C 90
C8 28 F 8 Ovary Mature teratoma - Benign Apocrine 2.5 M 100
C8 28 F 8 Ovary Mature teratoma - Benign Apocrine 1 C 50
C9 29 F 23 Ovary Mature teratoma - Benign Sebaceous 3 C 100
C9 29 F 23 Ovary Mature teratoma - Benign Skin 3 C 90
C10 30 F 26 Ovary Mature teratoma - Benign NR
D1 31 F 35 Ovary Mature teratoma - Benign Sebaceous 3 C 100
D1 31 F 35 Ovary Mature teratoma - Benign Apocrine 3 C 60
D2 32 F 47 Ovary Mature teratoma - Benign Skin 2 C 100
D2 32 F 47 Ovary Mature teratoma - Benign Sebaceous 3 C 100
D3 33 F 56 Ovary Mature teratoma - Benign Adipose 1 C 60
D3 33 F 56 Ovary Mature teratoma - Benign Adipose 3 M 40
D3 33 F 56 Ovary Mature teratoma - Benign Apocrine 3 C 70
D4 34 F 40 Ovary Mature teratoma - Benign NR
D5 35 F 32 Ovary Mature teratoma - Benign Skin 3 C 100
D5 35 F 32 Ovary Mature teratoma - Benign Sebaceous 3 C 100
D6 36 F 12 Ovary Mature teratoma - Benign Lymphocyte 3 N 40
D6 36 F 12 Ovary Mature teratoma - Benign Apocrine 3 C 70
D7 37 F 43 Ovary Mature teratoma - Benign NR
D8 38 F 27 Ovary Mature teratoma - Benign Skin 2 C 100
D9 39 F 22 Ovary Mature teratoma - Benign Sebaceous 3 C 100
D9 39 F 22 Ovary Mature teratoma - Benign Eccrine 1 C 30
D10 40 F 40 Ovary Mature teratoma - Benign Adipose 1 C 60
D10 40 F 40 Ovary Mature teratoma - Benign Adipose 3 M 30
D10 40 F 40 Ovary Mature teratoma - Benign Skin 3 C 100
E1 41 F 52 Ovary Mature teratoma - Benign Respiratory
epithelium
2.5 C 80
E2 42 F 23 Ovary Mature teratoma - Benign Sebaceous 3 C 100
E2 42 F 23 Ovary Mature teratoma - Benign Thyroid 1.5 C 70
E2 42 F 23 Ovary Mature teratoma - Benign Apocrine 2 C 70
E3 43 F 23 Ovary Mature teratoma - Benign Respiratory
epithelium
2 C 50
E3 43 F 23 Ovary Mature teratoma - Benign Lymphocytes 3 N 20
E4 44 F 47 Ovary Mature teratoma - Benign Skin 3 C 100
E4 44 F 47 Ovary Mature teratoma - Benign Nerve 3 NM 80
E4 44 F 47 Ovary Mature teratoma - Benign Nerve 2 C 70
E5 45 F 45 Ovary Mature teratoma - Benign Skin 3 C 100
E6 46 F 33 Ovary Mature teratoma - Benign Sebaceous 3 C 100
E6 46 F 33 Ovary Mature teratoma - Benign Respiratory
epithelium
1.5 C 100
E6 46 F 33 Ovary Mature teratoma - Benign Apocrine 2 C 70
E6 46 F 33 Ovary Mature teratoma - Benign Lymphocytes 3 N 5
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Table 1 Expression of CX3CR1 in human specimens of ovarian teratoma (Continued)
E7 47 F 27 Ovary Mature teratoma - Benign Sebaceous 2.5 C 100
E7 47 F 27 Ovary Mature teratoma - Benign Lymphocytes 3 N 30
E7 47 F 27 Ovary Mature teratoma - Benign Skin 2 C 90
E8 48 F 28 Ovary Mature teratoma - Benign Adipose 1 C 100
E8 48 F 28 Ovary Mature teratoma - Benign Adipose 3 M 50
E8 48 F 28 Ovary Mature teratoma - Benign Follicle 3 C 90
E9 49 F 24 Ovary Mature teratoma - Benign NR
E10 50 F 22 Ovary Mature teratoma - Benign Skin 3 C 100
F1 51 F 27 Ovary Mature teratoma
(ovary tissue)
- Benign NR
F2 52 F 32 Ovary Mature teratoma - Benign Lymphocytes 3 N 100
F3 53 F 42 Ovary Mature teratoma - Benign NR
F4 54 F 30 Ovary Mature teratoma - Benign Adipose 1 C 30
F4 54 F 30 Ovary Mature teratoma - Benign Adipose 3 M 15
F5 55 F 38 Ovary Mature teratoma - Benign Sebaceous 3 C 100
F5 55 F 38 Ovary Mature teratoma - Benign Skin 2.5 C 90
F5 55 F 38 Ovary Mature teratoma - Benign Lymphocytes 3 N 10
F6 56 F 36 Ovary Mature teratoma - Benign Sebaceous 3 C 100
F6 56 F 36 Ovary Mature teratoma - Benign Skin 3 C 100
F7 57 F 25 Ovary Mature teratoma - Benign Skin 3 C 100
F7 57 F 25 Ovary Mature teratoma - Benign Lymphocytes 3 N 90
F8 58 F 39 Ovary Mature teratoma - Benign Skin 3 C 100
F8 58 F 39 Ovary Mature teratoma - Benign Sebaceous 3 C 100
F9 59 F 32 Ovary Mature teratoma - Benign Sebaceous 3 C 100
F9 59 F 32 Ovary Mature teratoma - Benign Skin 3 C 100
F9 59 F 32 Ovary Mature teratoma - Benign Thyroid 2.5 C 50
F10 60 F 29 Ovary Mature teratoma - Benign Nerve 3 NM 100
F10 60 F 29 Ovary Mature teratoma - Benign Nerve 2.5 C 100
F10 60 F 29 Ovary Mature teratoma - Benign Adipose 1 C 10
F10 60 F 29 Ovary Mature teratoma - Benign Adipose 3 M 10
F10 60 F 29 Ovary Mature teratoma - Benign Follicle 2 C 100
F10 60 F 29 Ovary Mature teratoma - Benign Sebaceous 3 C 100
G1 61 F 32 Ovary Mature teratoma - Benign NR
G2 62 F 36 Ovary Mature teratoma - Benign Adipose 1 C 20
G2 62 F 36 Ovary Mature teratoma - Benign Adipose 3 M 10
G3 63 F 29 Ovary Mature teratoma - Benign NR
G4 64 F 39 Ovary Mature teratoma - Benign Nerve 3 NM 10
G5 65 F 15 Ovary Immature teratoma II Malignant Lymphocytes 3 N 10
G6 66 F 40 Ovary Immature teratoma - Malignant NR
G7 67 F 29 Ovary Immature teratoma - Malignant Immature 3 C/N 90
G8 68 F 37 Ovary Immature teratoma - Malignant Immature 2.5 C 100
G9 69 F 39 Ovary Mature teratoma - Benign Skin 3 C 100
G10 70 F 40 Ovary Mature teratoma - Benign Sebaceous 3 C 100
G10 70 F 40 Ovary Mature teratoma - Benign Skin 3 C 100
H1 71 F 49 Ovary Mature teratoma - Benign Adipose 1 C 30
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Table 1 Expression of CX3CR1 in human specimens of ovarian teratoma (Continued)
H1 71 F 49 Ovary Mature teratoma - Benign Adipose 3 M 10
H2 72 F 28 Ovary Immature teratoma II Malignant NR
H3 73 F 37 Ovary Immature teratoma - Malignant Immature 1 C 70
H4 74 F 22 Ovary Immature teratoma II Malignant Respiratory
epithelium
2 C 90
H4 74 F 22 Ovary Immature teratoma II Malignant Lymphocyte 3 N 30
H5 75 F 28 Ovary Immature teratoma II Malignant Adipose 1 C 100
H5 75 F 28 Ovary Immature teratoma II Malignant Respiratory
epithelium
2.5 C 100
H5 75 F 28 Ovary Immature teratoma II Malignant Sebaceous 1 C 70
H6 76 F 20 Ovary Immature teratoma II Malignant Immature 1.5 C 70
H7 77 F 18 Ovary Immature teratoma III Malignant Cystic epithelium 1.5 C 90
H8 78 M 45 Ovary Mature teratoma - Benign Sebaceous 2.5 C 100
H8 78 M 45 Ovary Mature teratoma - Benign Lymphocytes 3 N 50
H9 79 F 47 Ovary Malignant teratoma - Benign Apocrine 1.5 C 50
H10 80 F 69 Ovary Monodermal
teratoma
- Malignant Thyroid 2.5 C 40
H10 80 F 69 Ovary Monodermal
teratoma
- Malignant Lymphocytes 3 N 30
* Intensity was graded in the scale from 0 to 3; 0 - no staining, 1 - weak staining, 2 - moderate staining, 3 - strong staining.
** Location of the CX3CR1 staining was cytoplasmic (C), nuclear (N), and membranous (M), as indicated.
*** Percentage of CX3CR1-positive cells is indicated.
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Tissue microarray (TMA) slides containing specimens of
ovarian teratoma (Cat# OV805) and specimens of human
fetal tissues (Cat# BE01014) were obtained from US
Biomax (Rockville, MD). Because these specimens were
commercially available and were deidentified, no approvals
by the Institutional Review Board were required. GFP-
tagged CX3CR1 shRNA and scrambled shRNA constructs
were obtained from Origene Technologies (Rockville, MD).
DharmaFECT was obtained from Dharmacon (Lafayette,
CO). Matrigel was obtained from BD Biosciences (Bedford,
MA). Mouse monoclonal CK14 and CK18 and rabbit
polyclonal CX3CR1 (Cat# ab49747, ab49824, ab8021
and ab8020, respectively) antibodies were obtained from
Abcam (Cambridge, MA), and mouse monoclonal β-
tubulin antibody was obtained from Developmental
Studies Hybridoma Bank (Iowa City, IA), goat poly-
clonal CX3CL1 (Cat# AF365) was purchased from R&D
systems (Minneapolis, MN), and mouse monoclonal
actin antibody was purchased from Santa Cruz Biotech-
nology (Dallas, TX). Vectastain ABC and DAB kits were
obtained from Vector Laboratories (Burlingame, CA).
BMP-4 was purchased from Invitrogen (Carlsbad, CA).
Cell culture and directed differentiation
Ovarian teratocarcinoma cell line PA-1 and ovarian car-
cinoma cell line SKOV-3 were obtained from American
Tissue Culture Collection (Manassas, VA). PA-1 cellswere plated on Matrigel-coated (at 1/100 dilution) tissue
culture plates or glass cover slips at 5% confluence and
cultured in minimal essential media supplemented with
sodium pyruvate and non-essential amino acids for
2 weeks. Cells subjected to differentiation into skin
lineage were cultured in the above described media
containing 10 μg/ml BMP-4.
Immunohistochemical staining
TMA slides were deparaffinized by baking at 60°C for
2 h and rehydrated by incubation in xylene, 100% etha-
nol, 95% ethanol, 70% ethanol, and phosphate buffered
saline, pH 7.4, for 5 min each. Peroxidase activity was
inhibited with hydrogen peroxide. Antigen retrieval was
performed by 15 min incubation in 1 mM ethylene di-
amine tetraacetic acid (EDTA; pH 8.0) at 95°C. Prior to
primary antibody staining (1:50 dilution, rabbit anti-
human CX3CR1, Abcam Cat# ab8021, 1 h at room
temperature (RT)) non-specific binding was blocked by in-
cubation with 10% goat serum for 1 h. The biotin-
conjugated goat anti-rabbit secondary antibody was used
at a 1:200 dilution for 30 min at RT. The Vectashield ABC
kit was used as directed by the manufacturer, and tissues
were incubated for 45 min at RT. The DAB reagent was
prepared as instructed by the manufacturer and applied to
tissues on TMA slides for 2 – 10 min until brown color de-
veloped. TMAs were stained with hematoxylin, dehydrated
in 50%, 70%, 95%, and 100% ethanol, and mounted with
Permount. Pancreatic cancer tissue was used as a positive
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were both blinded to the experimental outcomes of the
study. Staining was scored based on the intensity and
percentage of positive cells. Intensity of staining was “0” for
negative samples, “1” for weakly positive samples, “2” for
moderately positive samples, and “3” for highly positive
samples. Overall scores were derived as the intensity score
multiplied by the percentage. Staining was assessed separ-
ately in the cytoplasm and the membrane.Cell transfection and generation of stable cell lines
PA-1 cells were cultured to 80% confluence and transfected
with either CX3CR1-specific GFP-tagged shRNA construct
or scrambled GFP-tagged shRNA construct (Origene
Technologies) using DharmaFECT according to the
manufacturer’s instructions. Selection of the clones was
performed with puromycin and green fluorescence as
suggested by the manufacturer.Immunofluorescence staining
Cells were cultured on glass coverslips to 50-70% con-
fluence, fixed, permeabilized with 0.01% Triton X-100,
and blocked in goat serum. Mouse monoclonal CK-14
(Cat# ab49747) antibody was used at a dilution of 1:50.
Cells were incubated with the primary antibodies for 1 h
at room temperature (22°C). The cells were then incu-
bated with secondary Alexa555-conjugated anti-mouse
antibodies (1:500) for 1 h at RT in the dark. 4’,6-
Diamidino-2-phenylindole (DAPI) was added to the
secondary antibody solution to a final concentration of
10 μg/ml 10 min prior to the end of the incubation
period. Cells were washed, air dried, and mounted on
glass slides using ProlongGold (Invitrogen, Carlsbad,
CA). Fluorescent imaging was performed using a Zeiss
AxioObserverD.1 fluorescent microscope.Figure 1 CX3CR1 is expressed in human ovarian teratoma.
Specimens of ovarian teratoma were examined for CX3CR1
expression by immunohistochemistry. Brown – CX3CR1; blue –
hematoxylin. Images were generated using an Aperio ScanScope
digital slide scanner. Magnification – 5×. A region outlined by a
dotted line is shown at 20× magnification. Cells of the sebaceous
gland, hair follicle, and skin are indicated.Western blotting
Western blotting analysis was used to detect the expression
of CK14, CK18, CX3CR1, CX3CL1, actin, and β-tubulin in
PA-1. This procedure was performed as previously de-
scribed [8,14,15] Antibodies were used at the following
dilutions: 1:500 mouse anti-human-CK14 or CK18, or
CX3CL1, rabbit anti-human CX3CR1 (Abcam ab8020)
and 1:200 mouse anti-human-β-tubulin or goat anti-
human actin in 3% BSA in a solution of 50 mM
tris-buffered saline, pH 7.4, 150 mM NaCl, and 0.05%
Tween-20 (TBST). Immunoreactive bands were visual-
ized with anti-(mouse-IgG)-peroxidase, anti-(goat-IgG)-
peroxidase, and anti-(rabbit-IgG)-peroxidase (Sigma, St.
Louis, MO) (1:1000 in 3% BSA in TBST), and enhanced
chemiluminescence was read using Chemidoc (Bio-Rad)
and Bio-Rad Chemidoc ImageReader software.Results
CX3CR1 is expressed in specimens of ovarian teratoma
According to our previous observations CX3CR1 was
expressed in cells comprising ovarian teratoma tissue
specimens [8], although the number of specimens was
very limited in order to be able to draw any conclusions.
In the present study we aimed to expand this observa-
tion on a larger number of ovarian teratoma specimens
and determine the predominant cell type(s) positive for
CX3CR1. Thus, we tested expression of CX3CR1 using a
tissue microarray containing 68 specimens of mature
ovarian teratoma, 10 specimens of immature teratoma,
and 2 cases of monodermal teratoma. Interestingly, we
have found that skin keratinocytes represent the most pre-
dominant CX3CR1-positive cell type, which was present
in 38% of tested cases of mature ovarian teratoma (Table 1,
Figure 1). The next most common CX3CR1-positive types
of cells in the tested cases of dermoid cyst were those
comprising the pilosebaceous unit of the skin assembled
of sebaceous gland and hair follicle (Table 1, Figure 1).
Table 2 Expression of CX3CR1 in human fetal tissues
Position Number Sex* Age* Organ* Type* Intensity** Location Percentage*** Score**** Notes
A1 1 M 5 mon. Heart Normal 2.5 100 250
A2 2 M 5 mon. Heart Normal 2.5 100 250
A3 3 M 5 mon. Heart Normal 2.5 100 250
A4 4 M 5 mon. Gallbladder Normal 2 100 200
A5 5 M 5 mon. Gallbladder Normal 2 60 120
A6 6 M 5 mon. Gallbladder Normal 2 90 180
A7 7 M 5 mon. Colon Normal 3 100 300
A8 8 M 5 mon. Colon Normal 3 100 300
A9 9 M 5 mon. Colon Normal 3 100 300
B1 10 M 5 mon. Small intestine Normal 2.5 100 250
B2 11 M 5 mon. Small intestine Normal 2.5 100 250
B3 12 M 5 mon. Small intestine Normal 2.5 100 250
B4 13 M 5 mon. Liver Normal 2.5 100 250
B5 14 M 5 mon. Liver Normal 3 100 300
B6 15 M 5 mon. Liver Normal 3 100 300
B7 16 M 5 mon. Rectum Normal 2.5 95 237.5
B8 17 M 5 mon. Rectum Normal 2 95 190
B9 18 M 5 mon. Rectum Normal 2.5 100 250
C1 19 M 5 mon. Stomach Normal 2 70 140
C2 20 M 5 mon. Stomach Normal 1.5 60 90
C3 21 M 5 mon. Stomach Normal 1.5 80 120
C4 22 M 5 mon. Adrenal gland Normal 2.5 80 200
C5 23 M 5 mon. Adrenal gland Normal 2 90 180
C6 24 M 5 mon. Adrenal gland Normal 2 60 120
C7 25 M 5 mon. Thyroid gland Normal 0.5 30 15
C8 26 M 5 mon. Thyroid gland Normal 0.5 10 5
C9 27 M 5 mon. Thyroid gland Normal 0.5 10 5
D1 28 M 5 mon. Spleen Normal 1 80 80
D2 29 M 5 mon. Spleen Normal 1 80 80
D3 30 M 5 mon. Spleen Normal 1 80 80
D4 31 M 5 mon. Thymus gland Normal 2.5 Epithelioid
cells
20 50
D4 1 Lymphocytes 100 100
D5 32 M 5 mon. Thymus gland Normal 2.5 Epithelioid
cells
20 50
D5 1 Lymphocytes 100 100
D6 33 M 5 mon. Thymus gland Normal 2.5 Epithelioid
cells
20 50
D6 1 Lymphocytes 100 100
D7 34 M 5 mon. Skin Normal 2 Epithelium 80 160
D7 3 Adipose 70 210
D8 35 M 5 mon. Skin Normal 1.5 Epithelium 80 120
D8 3 Adipose 70 210
D9 36 M 5 mon. Skin Normal 2 Epithelium 90 180
Rooper et al. Journal of Ovarian Research 2013, 6:57 Page 7 of 12
http://www.ovarianresearch.com/content/6/1/57
Table 2 Expression of CX3CR1 in human fetal tissues (Continued)
D9 3 Adipose 80 240
E1 37 M 5 mon. Bone Normal 2.5 30 75
E2 38 M 5 mon. Bone Normal 2.5 30 75
E3 39 M 5 mon. Bone Normal 2.5 30 75
E4 40 M 5 mon. Epididymis Normal 1 90 90
E5 41 M 5 mon. Epididymis Normal 0.5 60 30
E6 42 M 5 mon. Epididymis Normal 0.5 70 35
E7 43 M 5 mon. Brain Normal 2 20 40
E8 44 M 5 mon. Brain Normal 1 5 5
E9 45 M 5 mon. Brain Normal 1 5 5
F1 46 M 5 mon. Lung and trachea Normal 3 Trachea 90 270
F1 46 M 5 mon. Lung and trachea Normal 3 Alveoli 25 75
F2 47 M 5 mon. Lung and trachea Normal 3 Trachea 90 270
F2 47 M 5 mon. Lung and trachea Normal 1 Alveoli 25 25
F3 48 M 5 mon. Lung and trachea Normal 3 Trachea 80 240
F3 48 M 5 mon. Lung and trachea Normal 1 Alveoli 25 25
F4 49 M 5 mon. Muscle Normal 0.5 100 50
F5 50 M 5 mon. Muscle Normal 0.5 100 50
F6 51 M 5 mon. Muscle Normal 0.5 100 50
F7 52 M 5 mon. Smooth muscle Normal 2 100 200
F8 53 M 5 mon. Smooth muscle Normal 2 100 200
F9 54 M 5 mon. Smooth muscle Normal 2 100 200
G1 55 M 5 mon. Kidney Normal 2 Tubules 80 160
G1 55 M 5 mon. Kidney Normal 1 Glomeruli 50 50
G2 56 M 5 mon. Kidney Normal 2.5 Tubules 70 175
G2 56 M 5 mon. Kidney Normal 0.5 Glomeruli 30 15
G3 57 M 5 mon. Kidney Normal 1.5 Tubules 90 135
G3 57 M 5 mon. Kidney Normal 0.5 Glomeruli 70 35
G4 58 M 5 mon. Eye Normal 3 100 300 Retinal pigment
epithelium
G5 59 M 5 mon. Eye Normal 3 100 300 Retinal pigment
epithelium
G6 60 M 5 mon. Eye Normal 3 100 300 Retinal pigment
epithelium
G7 61 F 5 mon. Umbilical cord Normal 2 100 200
G8 62 F 5 mon. Umbilical cord Normal 1.5 100 150
G9 63 F 5 mon. Umbilical cord Normal NA NA NA
H1 64 F 5 mon. Placenta Normal 0.5 20 10
H2 65 F 5 mon. Placenta Normal 0.5 10 5
H3 66 F 5 mon. Placenta Normal 0.5 40 20
H4 67 F 5 mon. Uterus Normal 0.5 20 10
H5 68 F 5 mon. Uterus Normal 0.5 5 2.5
H6 69 F 5 mon. Uterus Normal 0.5 20 10
H7 70 F 5 mon. Pancreas Normal 2 Acini and
ducts
80 160
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Table 2 Expression of CX3CR1 in human fetal tissues (Continued)
H8 71 F 5 mon. Pancreas Normal 2.5 Acini and
ducts
80 200
H9 72 F 5 mon. Pancreas Normal 2.5 Acini and
ducts
70 175
I1 73 F 5 mon. Ovary Normal 3 70 210
I2 74 F 5 mon. Ovary Normal 3 80 240
I3 75 F 5 mon. Ovary Normal 3 90 270
I4 76 F 5 mon. Fallopian tube Normal 0.5 5 2.5
I5 77 F 5 mon. Fallopian tube Normal 1 10 10
I6 78 F 5 mon. Fallopian tube Normal 1.5 5 7.5
* Information obtained from the manufacturer (US Biomax; Rockville, MD) for the multiple organ fetal tissue array BE01014; TMA contained triplicate
cores (26cases/78cores).
** Intensity of staining was scored as negative (0), weak positive (1), moderate positive (2), and strong positive (3).
*** Denotes percentage of positive cells in the core.
**** Score has been calculated as intensity multiplied by percentage of positive cells.
Rooper et al. Journal of Ovarian Research 2013, 6:57 Page 9 of 12
http://www.ovarianresearch.com/content/6/1/57Other CX3CR1-positive cell types in the order of dimin-
ution included lymphatic, apocrine, adipose, thyroid, re-
spiratory epithelial, peripheral nervous, endothelial, and
eccrine (Table 1). Cases of tested immature ovarian tera-
toma were characterized by the presence of CX3CR1-posi-
tive brain, lymphatic, respiratory epithelial, adipose, and
sebaceous cells (Table 1). Two tested monodermal
teratomas consisted of CX3CR1-positive thyroid and
lymphatic tissues, respectively (Table 1). Thus, our data
suggest that skin keratinocytes are the predominant
type of CX3CR1-positive cells in the tested specimens of
mature ovarian teratomas.
CX3CR1 is expressed in fetal tissues
Further we wished to determine CX3CR1-positive cells
undergoing the normal development. We tested both
male and female fetal tissues aged 5 months in utero. We
found that the majority of epithelial cells, including skin
keratinocytes, were CX3CR1-positive (Table 2). Hence,
CX3CR1-positive skin cells are present not only within
abnormally differentiated tissues, such as mature ovarian
teratomas, but also in the normally developing skin.
CX3CR1 is required for keratinocyte differentiation
Based on our observations regarding CX3CR1 expression
in both normally and abnormally developing keratinocytes,
we hypothesized that CX3CR1 may be important for cell
differentiation into the epidermal lineage. Thus, we tested
the requirement for CX3CR1 in keratinocyte differentiation
using a cell culture model. Ovarian teratocarcinoma cell
line PA-1 has been established from the ascites of a patient
with malignant ovarian teratoma [16]. Chromosomal ana-
lysis had suggested that these cells have a heterozygous ori-
gin and derived at a stage prior to the first meiotic division
[17]. Several studies have shown that PA-1 is capable of
differentiation into diverse cell lineages at the appropriate
culture conditions [16,18,19]. Based on many similaritiesbetween the teratocarcinoma cells and early embryonic
cells, the former has been used to study processes of differ-
entiation [19,20]. Using gene specific shRNA constructs,
we downregulated CX3CR1 in PA-1 cell line (Figure 2A).
Further we cultured both CX3CR1sh-PA-1 and the control
cells transfected with a scrambled shRNA construct on
Matrigel in the presence and absence of 0.5 nM BMP-4
for 2 weeks. Expression of cytokeratin 14 (CK14) and
cytokeratin 18 (CK18) was analysed with immunofluor-
escence microscopy and Western blotting (Figure 2B,C).
We observed that only PA-1 transfected with scrambled
shRNA and cultured in BMP-4-supplemented media
expressed significantly higher levels of CK14 compared
to scrambled shRNA PA-1 or CX3CR1 shRNA PA-
1cultured in the absence of BMP-4, as well as CX3CR1
shRNA PA-1 cultured in the presence of BMP-4
(Figure 2B,C). In opposite, scrambled shRNA PA-1 or
CX3CR1 shRNA PA-1cultured in the absence of BMP-4,
as well as CX3CR1 shRNA PA-1 cultured in the presence
of BMP-4 expressed higher levels of CK18 compared to
scrambled shRNA PA-1 cultured in the presence of BMP-4
(Figure 2C). PA-1 expressed fractalkine ligand (CX3CL1)
necessary for the receptor (CX3CR1) activation (Figure 2D).
These data suggest that CX3CR1-positive PA-1 cells are
able to proceed toward differentiation into skin kera-
tinocytes in the presence of BMP-4 and begin express-
ing a marker of stratified epithelium CK14, while the
loss of CX3CR1 restricts differentiation and the cells re-
main CK18-positive simple-epithelial cells.
Discussion
Our findings demonstrate that cells of the skin lineage
comprise the most predominant CX3CR1-positive cell
type within the specimens of ovarian teratoma. Mature
skin is a predominant tissue found in mature ovarian
teratomas [21]. Our findings also show that normally de-
veloped keratinocytes are CX3CR1-positive. Importantly,
Figure 2 CX3CR1 is required for keratinocytes differentiation. (A) Expression of CX3CR1 in parental PA-1 cell line and that stably transfected
with either CX3CR1 or scrambled shRNA constructs was examined with Western blot. Actin served as a loading control. CX3CR1 expression levels
were quantified using digital densitometry and normalized to the levels of actin expression. (B) Expression of cytokeratin 14 in PA-1 cells stably
transfected with either CX3CR1 or scrambled shRNA constructs treated with recombinant BMP-4 or vehicle, as indicated, was examined with
immunocytochemistry. CK14 in PA-1 was probed with anti-CK14 and Alexa555-conjugated anti-rabbit antibodies, and DNA was stained with 4’,6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI); CK14 – red, DNA – blue. Images were taken using 5× magnification on the objective. The
histogram demonstrates the average intensity of CK14 signal across the field as determined by the Zeiss AxioVision software. Data is an average
of three independent experiments. *p < 0.05. (C) Expression of cytokeratins 14 and 18 in PA-1 cells stably transfected with either CX3CR1 or
scrambled shRNA constructs treated with recombinant BMP-4 or vehicle, as indicated, was examined with Western blot. β-Tubulin served as a
loading control. The histogram shows CK14 and CK18 expression levels. Expression of CK18 in CX3CR1shRNA-transfected PA-1 cells was arbitrarily
set as 1 and expression of both CK14 and CK18 in other conditions was calculated accordingly. The data represent a typical Western blot image,
and quantitative analysis was performed using three independently performed experiments. *p < 0.05. (D) Expression of CX3CL1 in SKOV-3 and
PA-1 cell lines was examined with Western blot. Actin served as a loading control. SKOV-3 cell line was used as a positive control.
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ant player in keratinocyte differentiation. Our data
indicate that teratocarcinoma cell line PA-1 expressed a
basal keratinocyte marker CK14 when cultured on
Matrigel in the presence of BMP-4. In opposite, cellswith silenced CX3CR1 and those cultured in the absence
of BMP-4 expressed CK18 specific for simple non-
stratified epithelium.
The role for CX3CR1 in skin differentiation has not
been described before, although, the role of this receptor
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ings could be potentially important, as skin is the largest
organ of the human body. Many pathological conditions
and injuries require regeneration of the skin, and affect-
ing the CX3CR1-dependent pathway could be one way
to achieving faster skin formation from cells capable of
differentiation. Thus, the studies of the role of CX3CR1
in keratinocyte differentiation need to be expanded further
to include more extensive studies on other abnormally dif-
ferentiating teratoma cell lines, as well as normally differ-
entiating embryonic stem cells. Furthermore, we observed
that CX3CR1 is expressed in other developing tissues, as
indicated in Table 2, thus, it is possible that this receptor
could be important for the development of those tissues
as well. In fact, a role for the fractalkine axis in osteoclasts
differentiation has been reported, whereby CX3CL1-ex-
pressing osteoblasts regulate differentiation of CX3CR1-
positive osteoclast precursors [12]. Hence, more rigorous
future studies of the role of CX3CR1 in development and
differentiation are required.
Conclusions
Here we present that fractalkine receptor is expressed
by skin cells in specimens of human ovarian teratoma
and fetus and is required for epidermal lineage differen-
tiation. This information sheds light on the ovarian
pathology, dermoid cyst, and outlines possible mecha-
nisms of cell differentiation within this benign forma-
tion. As the fractalkine receptor has recently emerged
as a novel potential therapeutic target against many
debilitating diseases, it is important to remember its
role in cell differentiation when applying future anti-
fractalkine therapies.
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